The Twist Diversity SNP Panel will help users determine disease mechanisms, identify drug targets, and speed drug development, according to the firm. The panel includes 1.4 million genetic variations called single-nucleotide polymorphisms (SNPs) and is the company's first release in its Targeted Genotyping-By-Sequencing portfolio, Twist said.

Twist said it plans to immediately begin marketing the assay under the Regeneron agreement.

Twist launches enzymatic fragmentation library prep kit
Twist Bioscience has unveiled its Twist Library Preparation Enzymatic Fragmentation Kit 2.0, an all-in-one solution designed to maximize accuracy and...

Twist announces Q2 financial results
Twist Bioscience announced that revenues grew in the company's second quarter of fiscal 2021, although the firm's net loss also grew.

Twist, Vivlion to generate gRNA libraries for CRISPR applications
Twist Bioscience and Vivlion are collaborating to generate guide RNA (gRNA) libraries for CRISPR genome engineering applications and target discovery...

NIH recommends outpatient use of Regeneron's COVID-19 antibody cocktail
Regeneron Pharmaceuticals said the U.S. National Institutes of Health (NIH) strongly recommends its Regen-CoV as an outpatient treatment for COVID-19...

Regeneron publishes data supporting Ab cocktail as passive COVID-19 vaccine
Regeneron said that interim data from its ongoing phase III clinical trial supports the use of its Regen-CoV antibody (Ab) cocktail as a passive vaccine...